Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Terry A Jacobson

Showing results (1-10 of 182) with videos related to

Pageof 19
Sort By:
Expert Opinion on Drug Safety|August 9, 2003
Combination lipid-lowering therapy with statins: safety issues in the postcerivastatin eraTerry A Jacobson
The American Journal of Cardiology|November 3, 2004
Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitorsTerry A Jacobson
Mayo Clinic Proceedings|April 3, 2010
A "hot" topic in dyslipidemia management--"how to beat a flush": optimizing niacin tolerability to promote long-term treatment adherence and coronary disease preventionTerry A Jacobson
The American Journal of Cardiology|April 4, 2006
Statin safety: lessons from new drug applications for marketed statinsTerry A Jacobson
The American Journal of Clinical Nutrition|June 11, 2008
Role of n-3 fatty acids in the treatment of hypertriglyceridemia and cardiovascular diseaseTerry A Jacobson
Expert Review of Cardiovascular Therapy|August 17, 2012
A new pure ω-3 eicosapentaenoic acid ethyl ester (AMR101) for the management of hypertriglyceridemia: the MARINE trialTerry A Jacobson
The American Journal of Cardiology|August 22, 2006
Secondary prevention of coronary artery disease with omega-3 fatty acidsTerry A Jacobson
Drug Safety|May 13, 2006
Overcoming 'ageism' bias in the treatment of hypercholesterolaemia : a review of safety issues with statins in the elderlyTerry A Jacobson
Mayo Clinic Proceedings|November 5, 2013
Lipoprotein(a), cardiovascular disease, and contemporary managementTerry A Jacobson
Mayo Clinic Proceedings|September 15, 2006
The safety of aggressive statin therapy: how much can low-density lipoprotein cholesterol be lowered?Terry A Jacobson
Pageof 19

Showing results (1-10 of 182) with videos related to

Sort By:
Pageof 19
Expert Opinion on Drug Safety|August 9, 2003
Combination lipid-lowering therapy with statins: safety issues in the postcerivastatin eraTerry A Jacobson
The American Journal of Cardiology|November 3, 2004
Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitorsTerry A Jacobson
Mayo Clinic Proceedings|April 3, 2010
A "hot" topic in dyslipidemia management--"how to beat a flush": optimizing niacin tolerability to promote long-term treatment adherence and coronary disease preventionTerry A Jacobson
The American Journal of Cardiology|April 4, 2006
Statin safety: lessons from new drug applications for marketed statinsTerry A Jacobson
The American Journal of Clinical Nutrition|June 11, 2008
Role of n-3 fatty acids in the treatment of hypertriglyceridemia and cardiovascular diseaseTerry A Jacobson
Expert Review of Cardiovascular Therapy|August 17, 2012
A new pure ω-3 eicosapentaenoic acid ethyl ester (AMR101) for the management of hypertriglyceridemia: the MARINE trialTerry A Jacobson
The American Journal of Cardiology|August 22, 2006
Secondary prevention of coronary artery disease with omega-3 fatty acidsTerry A Jacobson
Drug Safety|May 13, 2006
Overcoming 'ageism' bias in the treatment of hypercholesterolaemia : a review of safety issues with statins in the elderlyTerry A Jacobson
Mayo Clinic Proceedings|November 5, 2013
Lipoprotein(a), cardiovascular disease, and contemporary managementTerry A Jacobson
Mayo Clinic Proceedings|September 15, 2006
The safety of aggressive statin therapy: how much can low-density lipoprotein cholesterol be lowered?Terry A Jacobson
Pageof 19